TVTX logo

Travere Therapeutics, Inc. (TVTX) Cash from operations

annual CFO:

-$237.47M+$42.55M(+15.19%)
December 31, 2024

Summary

  • As of today (September 16, 2025), TVTX annual cash flow from operations is -$237.47 million, with the most recent change of +$42.55 million (+15.19%) on December 31, 2024.
  • During the last 3 years, TVTX annual CFO has fallen by -$222.68 million (-1505.43%).
  • TVTX annual CFO is now -3307.82% below its all-time high of $7.40 million, reached on December 31, 2017.

Performance

TVTX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

quarterly CFO:

$4.98M+$47.18M(+111.81%)
June 30, 2025

Summary

  • As of today (September 16, 2025), TVTX quarterly cash flow from operations is $4.98 million, with the most recent change of +$47.18 million (+111.81%) on June 30, 2025.
  • Over the past year, TVTX quarterly CFO has increased by +$45.23 million (+112.38%).
  • TVTX quarterly CFO is now -84.46% below its all-time high of $32.06 million, reached on September 30, 2021.

Performance

TVTX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

TTM CFO:

-$115.44M+$45.23M(+28.15%)
June 30, 2025

Summary

  • As of today (September 16, 2025), TVTX TTM cash flow from operations is -$115.44 million, with the most recent change of +$45.23 million (+28.15%) on June 30, 2025.
  • Over the past year, TVTX TTM CFO has increased by +$173.42 million (+60.04%).
  • TVTX TTM CFO is now -1659.34% below its all-time high of $7.40 million, reached on December 31, 2017.

Performance

TVTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

TVTX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+15.2%+112.4%+60.0%
3 y3 years-1505.4%+113.5%-32.8%
5 y5 years-307.9%+177.2%-112.9%

TVTX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-1505.4%+15.2%at high+104.2%-32.8%+63.7%
5 y5-year-1505.4%+15.2%-84.5%+104.2%-6367.1%+63.7%
alltimeall time-3307.8%+15.2%-84.5%+104.2%-1659.3%+63.7%

TVTX Cash from operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$4.98M(-111.8%)
-$115.44M(-28.1%)
Mar 2025
-
-$42.19M(+18.1%)
-$160.66M(-32.3%)
Dec 2024
-$237.47M(-15.2%)
-$35.72M(-16.0%)
-$237.47M(-12.8%)
Sep 2024
-
-$42.51M(+5.6%)
-$272.23M(-5.8%)
Jun 2024
-
-$40.24M(-66.2%)
-$288.86M(-9.1%)
Mar 2024
-
-$119.00M(+68.9%)
-$317.91M(+13.5%)
Dec 2023
-$280.02M(+50.3%)
-$70.47M(+19.2%)
-$280.02M(+6.0%)
Sep 2023
-
-$59.13M(-14.7%)
-$264.19M(+8.0%)
Jun 2023
-
-$69.30M(-14.6%)
-$244.58M(+15.3%)
Mar 2023
-
-$81.12M(+48.5%)
-$212.09M(+13.8%)
Dec 2022
-$186.29M(+1159.4%)
-$54.64M(+38.2%)
-$186.29M(+17.5%)
Sep 2022
-
-$39.52M(+7.4%)
-$158.53M(+82.3%)
Jun 2022
-
-$36.81M(-33.5%)
-$86.94M(+99.2%)
Mar 2022
-
-$55.32M(+105.8%)
-$43.64M(+195.0%)
Dec 2021
-$14.79M(-65.4%)
-$26.88M(-183.8%)
-$14.79M(+728.7%)
Sep 2021
-
$32.06M(+393.6%)
-$1.78M(-93.4%)
Jun 2021
-
$6.50M(-124.5%)
-$27.11M(-32.3%)
Mar 2021
-
-$26.47M(+90.9%)
-$40.06M(-6.3%)
Dec 2020
-$42.74M(-26.6%)
-$13.87M(-305.9%)
-$42.74M(+28.1%)
Sep 2020
-
$6.74M(-204.4%)
-$33.37M(-38.5%)
Jun 2020
-
-$6.45M(-77.9%)
-$54.22M(-18.9%)
Mar 2020
-
-$29.16M(+549.0%)
-$66.88M(+14.9%)
Dec 2019
-$58.21M(+133.2%)
-$4.49M(-68.2%)
-$58.21M(+1.6%)
Sep 2019
-
-$14.12M(-26.1%)
-$57.29M(+21.7%)
Jun 2019
-
-$19.11M(-6.7%)
-$47.06M(+53.2%)
Mar 2019
-
-$20.49M(+474.8%)
-$30.72M(+23.1%)
Dec 2018
-$24.96M(-437.1%)
-$3.56M(-8.6%)
-$24.96M(+12.2%)
Sep 2018
-
-$3.90M(+41.3%)
-$22.25M(+83.1%)
Jun 2018
-
-$2.76M(-81.3%)
-$12.15M(+166.7%)
Mar 2018
-
-$14.73M(+1625.3%)
-$4.55M(-161.5%)
Dec 2017
$7.40M
-$854.00K(-113.8%)
$7.40M(+395.5%)
Sep 2017
-
$6.20M(+28.2%)
$1.49M(+3635.0%)
Jun 2017
-
$4.83M(-274.2%)
$40.00K(-105.0%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$2.78M(-59.0%)
-$805.00K(-49.6%)
Dec 2016
-$1.60M(+188.1%)
-$6.76M(-242.6%)
-$1.60M(-161.0%)
Sep 2016
-
$4.74M(+18.9%)
$2.62M(-475.6%)
Jun 2016
-
$3.99M(-211.9%)
-$697.00K(-121.7%)
Mar 2016
-
-$3.57M(+39.9%)
$3.21M(-679.9%)
Dec 2015
-$554.00K(-98.8%)
-$2.55M(-278.4%)
-$554.00K(-92.2%)
Sep 2015
-
$1.43M(-81.9%)
-$7.10M(-70.5%)
Jun 2015
-
$7.90M(-207.7%)
-$24.03M(-44.6%)
Mar 2015
-
-$7.33M(-19.4%)
-$43.38M(-5.4%)
Dec 2014
-$45.85M(+160.7%)
-$9.09M(-41.3%)
-$45.85M(+2.1%)
Sep 2014
-
-$15.50M(+35.4%)
-$44.90M(+40.1%)
Jun 2014
-
-$11.45M(+16.8%)
-$32.06M(+40.5%)
Mar 2014
-
-$9.81M(+20.4%)
-$22.82M(+29.7%)
Dec 2013
-$17.59M(+542.7%)
-$8.15M(+206.8%)
-$17.59M(+86.3%)
Sep 2013
-
-$2.66M(+20.2%)
-$9.44M(+39.1%)
Jun 2013
-
-$2.21M(-51.8%)
-$6.79M(+48.2%)
Mar 2013
-
-$4.58M(<-9900.0%)
-$4.58M(>+9900.0%)
Dec 2012
-$2.74M(>+9900.0%)
-
-
Nov 2011
-
$0.00(0.0%)
-$600.00(-14.3%)
Aug 2011
-
$0.00(0.0%)
-$700.00(0.0%)
May 2011
-
$0.00(-100.0%)
-$700.00(0.0%)
Feb 2011
-$700.00(+600.0%)
-$600.00(+500.0%)
-$700.00(+600.0%)
Nov 2010
-
-$100.00(<-9900.0%)
-$100.00(<-9900.0%)
Aug 2010
-
$0.00(0.0%)
$0.00(-100.0%)
May 2010
-
$0.00(0.0%)
-$100.00(0.0%)
Feb 2010
-$100.00(-99.5%)
$0.00(0.0%)
-$100.00(0.0%)
Nov 2009
-
$0.00(-100.0%)
-$100.00(-66.7%)
Aug 2009
-
-$100.00(<-9900.0%)
-$300.00(+50.0%)
May 2009
-
$0.00(0.0%)
-$200.00(-99.0%)
Feb 2009
-$20.20K(<-9900.0%)
$0.00(-100.0%)
-$20.20K(0.0%)
Nov 2008
-
-$200.00(<-9900.0%)
-$20.20K(+1.0%)
Aug 2008
-
$0.00(-100.0%)
-$20.00K(0.0%)
May 2008
-
-$20.00K
-$20.00K
Feb 2008
$0.00
-
-

FAQ

  • What is Travere Therapeutics, Inc. annual cash flow from operations?
  • What is the all time high annual CFO for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. annual CFO year-on-year change?
  • What is Travere Therapeutics, Inc. quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. quarterly CFO year-on-year change?
  • What is Travere Therapeutics, Inc. TTM cash flow from operations?
  • What is the all time high TTM CFO for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. TTM CFO year-on-year change?

What is Travere Therapeutics, Inc. annual cash flow from operations?

The current annual CFO of TVTX is -$237.47M

What is the all time high annual CFO for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high annual cash flow from operations is $7.40M

What is Travere Therapeutics, Inc. annual CFO year-on-year change?

Over the past year, TVTX annual cash flow from operations has changed by +$42.55M (+15.19%)

What is Travere Therapeutics, Inc. quarterly cash flow from operations?

The current quarterly CFO of TVTX is $4.98M

What is the all time high quarterly CFO for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high quarterly cash flow from operations is $32.06M

What is Travere Therapeutics, Inc. quarterly CFO year-on-year change?

Over the past year, TVTX quarterly cash flow from operations has changed by +$45.23M (+112.38%)

What is Travere Therapeutics, Inc. TTM cash flow from operations?

The current TTM CFO of TVTX is -$115.44M

What is the all time high TTM CFO for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high TTM cash flow from operations is $7.40M

What is Travere Therapeutics, Inc. TTM CFO year-on-year change?

Over the past year, TVTX TTM cash flow from operations has changed by +$173.42M (+60.04%)
On this page